Dr. Thierry Facon making a compelling argument for autologous stem cell transplant for newly diagnosed myeloma. @Myeloma_Society #IMS2022 
For high risk myeloma, its important to consider early transplant in the frontline setting.
For standard risk myeloma, we continue to prefer early transplant but in certain circumstance can delay transplant until first relapse accommodating patients’ wishes & life circumstances
For standard risk myeloma, we continue to prefer early transplant but in certain circumstance can delay transplant until first relapse accommodating patients’ wishes & life circumstances
https://twitter.com/vincentrk/status/1534113835241639942
For patients achieving MRD negative with induction therapy alone, early and delayed transplant gives similar outcomes. Thus an MRD directed approach to timing of transplant may the way of the future. Agree with @mvmateos #IMS2022
To emphasize for transplant eligible patients the importance of transplant in myeloma is not in question. The current debate post IFM and DETERMINATION trials is only concerning its timing. #IMS2022
The audience @Myeloma_Society when polled overwhelmingly support the role of transplant in myeloma. Like 99 to 1!
#IMS2022
#IMS2022
The MIDAS trial in IFM (France) is randomizing MRD negative patients to transplant vs no transplant. @End_myeloma is also leading a similar trial.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
